| |
| |
|
| Insider
Information: |
Ratcliffe Liam |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
14 |
|
| Direct
Shares |
5,450,392 |
|
|
Indirect Shares
|
11,059,115 |
|
|
| Direct
Value |
$32,761,423 |
|
|
|
Indirect Value
|
$72,370,072 |
|
|
| Total
Shares |
16,509,507 |
|
|
| Total
Value |
$105,131,495 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
11
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
1
|
11
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-11.0
|
| Percentage
Gain/Loss : |
 11.6%
|
 -418.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Relypsa Inc |
RLYP |
Former 10% beneficial ... |
2013-11-20 |
0 |
2013-11-20 |
2,114,890 |
Premium* |
|
|
Oxford Immunotec Global Plc |
OXFD |
10% Owner |
2013-11-21 |
1,377,497 |
|
0 |
Premium* |
|
|
MEI Pharma Inc |
MEIP |
10% Owner |
2015-03-24 |
0 |
2013-11-21 |
0 |
Premium* |
|
|
Concert Pharmaceuticals, Inc. |
CNCE |
10% Owner |
2014-02-19 |
107,327 |
|
0 |
Premium* |
|
|
Chimerix Inc |
CMRX |
10% Owner |
2014-03-18 |
1,543,394 |
2014-03-18 |
0 |
Premium* |
|
|
Aravive Inc |
ARAV |
10% Owner |
2014-12-18 |
2,409,374 |
2014-03-27 |
0 |
Premium* |
|
|
Durata Therapeutics, Inc. |
DRTX |
10% Owner |
2014-11-17 |
0 |
2014-11-17 |
0 |
Premium* |
|
|
Cogent Biosciences, Inc. |
COGT |
Director |
2018-04-03 |
0 |
2018-04-03 |
897,773 |
Premium* |
|
|
Deciphera Pharmaceuticals, Inc. |
DCPH |
Director, 10% Owner |
2017-10-02 |
0 |
2017-10-02 |
2,146,308 |
Premium* |
|
|
Iterum Therapeutics Plc |
ITRM |
10% Owner |
2018-05-30 |
0 |
2018-05-30 |
384,615 |
Premium* |
|
|
Aptinyx Inc. |
APTX |
Director, 10% Owner |
2018-06-25 |
0 |
2018-06-25 |
368,345 |
Premium* |
|
|
Arvinas Holding Company, Llc |
ARVN |
Director |
2021-11-05 |
0 |
2021-12-16 |
185,686 |
Premium* |
|
|
PDS Biotechnology Corp |
PDSB |
Director |
2019-03-15 |
10,000 |
2019-03-15 |
2,344,868 |
Premium* |
|
|
Passage Bio, Inc. |
PASG |
Director |
2020-03-03 |
2,800 |
2020-03-03 |
2,616,630 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-12-16 |
4 |
S |
$68.97 |
$5,944,418 |
I/I |
(85,705) |
185,686 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-12-15 |
4 |
S |
$65.74 |
$7,584,964 |
I/I |
(113,536) |
271,391 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-12-14 |
4 |
S |
$64.20 |
$10,303,999 |
I/I |
(156,464) |
384,927 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-11-15 |
4 |
S |
$83.90 |
$1,806,469 |
I/I |
(21,284) |
541,391 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-11-12 |
4 |
S |
$84.02 |
$3,386,461 |
I/I |
(39,869) |
562,675 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-11-11 |
4 |
S |
$85.92 |
$5,156,393 |
I/I |
(59,799) |
602,544 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-11-10 |
4 |
S |
$86.59 |
$1,178,188 |
I/I |
(13,358) |
662,343 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-11-09 |
4 |
S |
$91.33 |
$3,035,861 |
I/I |
(33,008) |
675,701 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-11-08 |
4 |
S |
$92.48 |
$7,655,882 |
I/I |
(81,054) |
708,709 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-11-05 |
4 |
S |
$89.86 |
$3,039,319 |
I/I |
(33,094) |
789,763 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-11-05 |
4 |
S |
$89.65 |
$2,275,362 |
D/D |
(24,923) |
0 |
0 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2021-11-05 |
4 |
OE |
$22.06 |
$544,531 |
D/D |
18,423 |
24,923 |
0 |
- |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2020-12-18 |
4 |
B |
$70.00 |
$9,999,990 |
I/I |
142,857 |
822,857 |
2.1 |
% |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2020-05-26 |
4 |
OE |
$22.06 |
$143,390 |
D/D |
6,500 |
6,500 |
0 |
- |
|
| PASG |
Passage Bio, Inc. |
Director |
– • – |
2020-03-03 |
4 |
B |
$18.00 |
$50,400 |
D/D |
2,800 |
2,800 |
2.39 |
% |
|
| PASG |
Passage Bio, Inc. |
Director |
– • – |
2020-03-03 |
4/A |
A |
$0.00 |
$0 |
I/I |
2,066,630 |
2,066,630 |
0 |
- |
|
| PASG |
Passage Bio, Inc. |
Director |
– • – |
2020-03-03 |
4/A |
B |
$18.00 |
$9,900,000 |
I/I |
550,000 |
2,616,630 |
2.1 |
- |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2019-11-12 |
4 |
B |
$22.00 |
$14,960,000 |
I/I |
680,000 |
680,000 |
2.1 |
- |
|
| PDSB |
PDS Biotechnology Corp |
Director |
• • – |
2019-03-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2018-10-01 |
4 |
B |
$16.00 |
$16,000,000 |
I/I |
1,000,000 |
375,000 |
2.1 |
- |
|
| ARVN |
Arvinas Holding Company, ... |
Director |
– • – |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,283,048 |
1,283,048 |
0 |
- |
|
| APTX |
Aptinyx Inc. |
Director |
– • • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,079 |
243,345 |
0 |
- |
|
| APTX |
Aptinyx Inc. |
Director |
– • • |
2018-06-25 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
368,345 |
2.25 |
- |
|
| ITRM |
Iterum Therapeutics Plc |
10% Owner |
– – • |
2018-05-30 |
4 |
B |
$13.00 |
$8,614,801 |
I/I |
662,677 |
384,615 |
1.5 |
- |
|
| ITRM |
Iterum Therapeutics Plc |
10% Owner |
– – • |
2018-05-30 |
4 |
A |
$0.00 |
$0 |
I/I |
793,626 |
793,626 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
